Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036. The options vest in equal monthly installments over three years from August 1, 2026 through August 1, 2029, subject to continuous service, resulting in 18,000 options directly held after this award.
Kalaris Therapeutics, Inc. reports that Laurie Keating is a director in an initial insider ownership statement. The report lists no transactions and shows no securities entries as beneficially owned in the data provided. Remarks reference Exhibit 24.1, described as a Power of Attorney.
Kalaris Therapeutics, Inc. officer Amy O'Leary Vandekop filed an initial statement of beneficial ownership. She reports direct ownership of 948 shares of common stock and two stock options over 27,415 shares at $7.31 expiring April 9, 2035 and 20,000 shares at $6.81 expiring March 18, 2036. Footnotes state the options were granted in April 2025 and March 2026, with 25% vesting on March 18, 2026 and March 19, 2027, respectively, and the remaining shares vesting in equal monthly installments through 2029 and 2030.
Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko. On July 20, 2026, she received a stock option to acquire 220,000 shares of common stock at an exercise price of $4.00 per share, expiring on July 19, 2036.
According to the vesting schedule, 25% of the underlying shares vest on July 20, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. Following this award, she holds options covering 220,000 shares.
Kalaris Therapeutics, Inc. lists Liisa Ann Bayko, its Chief Financial Officer, as a reporting person on Form 3. The Form 3 data show no equity holdings, derivative positions, or buy or sell transactions currently reported for her in Kalaris Therapeutics securities.
Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer, Treasurer and principal financial officer effective July 20, 2026. Her Employment Agreement provides a base salary of $475,000, eligibility for an annual bonus of up to 40.0% of base salary, and standard non‑competition, non‑solicitation and confidentiality covenants.
Bayko received an incentive stock option to purchase 220,000 shares of common stock, with an exercise price set at the Nasdaq closing price on the effective date. The option vests 25% on the first anniversary of her start date and monthly over 36 months thereafter, subject to continued service. If terminated without cause or for good reason outside a change in control window, she may receive nine months of base salary and COBRA premium support; this increases to 12 months of salary, a bonus equal to 100% of target, extended COBRA premium support and full time‑based equity vesting if such a termination occurs in proximity to a change in control.
Brett Hagen resigned as Senior Vice President, Finance and Chief Accounting Officer effective July 27, 2026. The Board designated Amy Vandekop, Corporate Controller, as interim principal accounting officer effective the same date, with no changes to her existing compensation arrangements. Both Bayko and Vandekop entered into indemnification agreements covering certain legal expenses arising from their service as officers.
Kalaris Therapeutics reported positive additional data from its expanded Phase 1a single ascending dose trial of TH103 in treatment-naïve neovascular age-related macular degeneration. The dataset now covers 17 treatment-naïve and 3 treatment-experienced patients, all followed for six months, and continues to show robust structural and functional vision improvements.
TH103 demonstrated pharmacokinetics suggesting extended intraocular retention, with 27- to 53-fold lower plasma Cmax than leading anti-VEGF agents on a molar basis. After a single injection, 41% of treatment-naïve patients were retreated at four months or later and 29% needed no additional anti-VEGF therapy over six months; treatment-experienced patients saw an average two‑month extension in retreatment intervals. No intraocular inflammation occurred in six patients at the 2.5 mg dose produced with an improved process, while one prior 5 mg patient had transient inflammation that resolved. Kalaris is enrolling a Phase 1b/2 multiple-ascending dose study using a four-dose loading regimen in treatment-naïve patients and remains on track to share initial data in the first half of 2027; investor materials also indicate cash runway into Q4 2027.
Kalaris Therapeutics reported a board change and related director compensation. Morana Jovan-Embiricos, Ph.D., resigned from the board and the Audit Committee, and stated her resignation was not due to any disagreement with the company’s operations, policies or practices.
The board elected Laurie Keating as a Class I director, effective August 1, 2026, with a term running to the 2027 annual meeting. She will also join the Audit Committee. As a non-employee director, she will receive an option for 18,000 shares vesting over three years, annual cash fees for board and committee service, ongoing equity grants under the director compensation policy and standard indemnification protection.
Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.7200 per share and expires on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service. Following this grant, Morana holds options to purchase 9,000 shares directly.
Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock. The options have an exercise price of $4.7200 per share and expire on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service.